Clinical News

Inside the U.S., European markets for biosimilarsDespite barriers to their adoption in the U.S. and Europe, biosimilars have produced healthcare savings in Europe. Similar savings are projected for the U.S. market.
Biosimilars for cancer treatment on the U.S. horizonCancer treatments are expected to dominate much of the first wave of biosimilars in the U.S. This Q&A discussion looks at some of the questions pharmacists have about use of biosimilars in cancer treatment.
Adding biosimilars to formularies: The pharmacist's rolePharmacists on P&T committees are going to face issues that range from biosimilar naming systems to challenges in dispensing and costs.
Biosimilar: Coming to a pharmacy near youBiosimilars are the future of pharmacy. When they hit community pharmacy, issues that have been important in specialty settings are going to explode.
Compression stockings, AF patients at risk, and ICH outcomesAnticoagulation briefs.
FDA approves brivaracetam for use in partial onset seizure treatmentBrivaracetam provides another adjunctive treatment option for partial onset seizures in patients with uncontrolled epilepsy.
Long-term safety of glycopyrrolate: A randomized study of COPD patientsGlycopyrrolate bromide is a quick-onset long-acting muscarinic antagonist bronchodilator with FDA approval for use as maintenance treatment of COPD. Seebri Neohaler is approved for use at a dose of 15.6 ug inhaled twice daily.
Dual therapy strategies for COPD: The scientific rationale for LAMA & LABAThere is a growing group of LAMA/LABA combination therapies in development. Investigations into the risks and benefits of LAMA/LABA therapy have demonstrated benefits.
PBM giants pare down drug expenses
PBM giants pare down drug expensesWhen Express Scripts and CVS Health announced their 2017 formularies on August 1, a common theme emerged among the healthcare giants: several blockbuster drugs will be removed from both companies’ formularies and lower-cost options such as biosimilars are being embraced.
ASPs vs. microbial resistance: Pharmacists lead the chargeThe Pew Charitable Trusts took a look at antibiotic stewardship programs in 10 U.S. health systems. Here's the result.